# Seagen Inc. clinical trials: 88 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 88 trials with Seagen Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Seagen Inc.: 88 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/seagen-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 88
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 88, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 12, 2024 | NCT06362590 | Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors | Seagen Inc. | Not applicable | Available |  | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06362590) |
| February 17, 2022 | NCT05244473 | A Safety Study of Brentuximab Vedotin in Participants With HIV | Seagen Inc. | Phase 1 | Withdrawn | Human Immunodeficiency Virus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05244473) |
| February 8, 2022 | NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | Seagen Inc. | Phase 1 | Terminated | Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction... | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05229900) |
| August 6, 2021 | NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | Seagen Inc. | Phase 2 | Completed | Melanoma, Carcinoma, Non-Small- Cell Lung | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04993677) |
| December 14, 2020 | NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Seagen Inc. | Phase 1 | Terminated | Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04665921) |
| August 5, 2020 | NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | Seagen Inc. | Phase 2/3 | Completed | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04499924) |
| February 5, 2020 | NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Seagen Inc. | Phase 1 | Terminated | Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse... | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04254107) |
| August 2, 2019 | NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Seagen Inc. | Phase 1 | Terminated | Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal... | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04042480) |
| July 25, 2019 | NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Seagen Inc. | Phase 2 | Terminated | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck... | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04032704) |
| May 21, 2019 | NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Seagen Inc. | Phase 1 | Terminated | Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03957096) |
| May 13, 2019 | NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | Seagen Inc. | Phase 2 | Terminated | Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03947255) |
| April 16, 2019 | NCT03914755 | A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects | Seagen Inc. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03914755) |
| February 1, 2019 | NCT03826602 | A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin | Seagen Inc. | Phase 1 | Completed | Drug-drug Interaction | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03826602) |
| December 17, 2018 | NCT03777761 | Effects of Tucatinib on Cardiac Repolarization in Healthy Participants | Seagen Inc. | Phase 1 | Completed | Healthy | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03777761) |
| October 29, 2018 | NCT03723395 | A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib | Seagen Inc. | Phase 1 | Completed | Drug-drug Interaction | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03723395) |
| October 29, 2018 | NCT03722823 | A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects | Seagen Inc. | Phase 1 | Completed | Hepatic Impairment | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03722823) |
| September 4, 2018 | NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | Seagen Inc. | Phase 2 | Completed | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03657043) |
| August 24, 2018 | NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Seagen Inc. | Phase 2 | Terminated | Hodgkin Lymphoma | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03646123) |
| July 10, 2018 | NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Seagen Inc. | Phase 1 | Terminated | Multiple Myeloma | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03582033) |
| February 19, 2018 | NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | Seagen Inc. | Phase 2 | Completed | Cervical Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03438396) |
| February 7, 2018 | NCT03424473 | Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer | Seagen Inc. | Not applicable | No longer available |  | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03424473) |
| December 20, 2017 | NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | Seagen Inc. | Phase 1 | Terminated | Multiple Myeloma | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03379584) |
| October 16, 2017 | NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Seagen Inc. | Phase 1/2 | Completed | Triple Negative Breast Neoplasms | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03310957) |
| August 10, 2017 | NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Seagen Inc. | Phase 2 | Completed | Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer... | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03245736) |
| February 6, 2017 | NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Seagen Inc. | Phase 2 | Completed | Metastatic Colorectal Adenocarcinoma | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03043313) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 42 |
| Phase 1/2 | 9 |
| Phase 2 | 30 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Not applicable | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 56 |
| Terminated | 28 |
| No longer available | 2 |
| Withdrawn | 1 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hematologic Diseases | 30 |
| Lymphoma | 22 |
| Lymphoma, Non-Hodgkin | 18 |
| Hodgkin Disease | 16 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Lymphoma, Large B-Cell, Diffuse | 12 |
| Lymphoma, Large-Cell, Anaplastic | 11 |
| Ovarian Neoplasms | 9 |
| Immunoproliferative Disorders | 8 |
| Leukemia, Myeloid, Acute | 8 |
| Lymphoma, B-Cell | 8 |
| Breast Neoplasms | 8 |
| Uterine Cervical Neoplasms | 7 |
| Lymphoproliferative Disorders | 7 |
| Neoplasms | 7 |
| Lymphatic Diseases | 7 |
| Squamous Cell Carcinoma of Head and Neck | 7 |
| Lymphoma, Follicular | 6 |
| Melanoma | 6 |
| Endometrial Neoplasms | 5 |
| Urinary Bladder Neoplasms | 5 |
| Prostatic Neoplasms | 5 |
| Multiple Myeloma | 5 |
| Stomach Neoplasms | 5 |
| Colorectal Neoplasms | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [High schools in the United States](https://specstream.ai/data/businesses/high-schools/united-states)
- [Mechanical engineering firms in the United States](https://specstream.ai/data/businesses/mechanical-engineering-firms/united-states)
- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Advertising agencies in the United States](https://specstream.ai/data/businesses/advertising-agencies/united-states)
- [Brazilian restaurants in the United States](https://specstream.ai/data/businesses/brazilian-restaurants/united-states)
